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Abstract
Objectives: The impact of pre-transplant hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection
in patients with hepatocellular carcinoma (HCC) is not well described. This study was conducted to test
the hypothesis that viral status is an independent predictor of retransplantation rates, graft survival (GS)
and overall survival (OS) in patients undergoing liver transplantation for HCC.
Methods: Patients with HCC were identified from the Organ Procurement and Transplantation Network
database (2005–2012), and categorized by viral status according to these categories: HBV-/HCV-;
HBV+/HCV-; HBV-/HCV+, and HBV+/HCV+.
Results: Of 7742 patients transplanted for HCC, 7060 had known HBV and HCV status. Five-year GS
and OS were highest in recipients who were HBV+/HCV-, at 75% and 78%, respectively, compared with
patients who were HBV-/HCV- (GS = 63%, OS = 66%), HBV-/HCV+ (GS = 64%, OS = 60%) or
HBV+/HCV+ (GS = 60%, OS = 62%). In multivariable analyses, HBV-/HCV+ patients were more likely than
HBV+/HCV- patients to undergo repeat transplantation. Patients who were HBV-/HCV+ also had poorer
GS and OS than both HBV-/HCV- and HBV+/HCV- patients. Other independent predictors of poorer OS
included older age, higher Model for End-stage Liver Disease score, African-American race, and diabetes.
The few HBV+/HCV+ patients (n = 138) showed trends toward fewer retransplantations, prolonged GS
and prolonged OS compared with HBV-/HCV+ patients. In adjusted models, antiviral medications did not
impact GS or OS.
Conclusions: In the era of modern selection criteria, viral status is an independent predictor of outcome
following liver transplantation for HCC. Both HBV-/HCV- and HBV+/HCV- patients have superior GS and
OS compared with HBV-/HCV+ patients.
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Introduction
Hepatocellular carcinoma (HCC) is the world’s most common
solid-organ tumour and third most common cause of cancer-
related death worldwide (600 000 deaths/year).1–4 The incidence
of HCC has increased over the past several decades5 and may not
plateau for the next 10 years.6 Because HCC often arises in the
setting of background liver disease, liver transplantation is an ideal
treatment that enables the excision of the tumour and the replace-
ment of the underlying tumorigenic parenchyma. Early experi-
ence with transplantation in HCC was associated with relatively
low 5-year survival rates of 30–40%.7 Eventually, patients with
more extensive disease were noted to have increased recurrence
rates and poorer survival.8 Since the adoption of modern selection
criteria (the Milan Criteria) for liver transplantation in the setting
of HCC,7 many centres have reported 5-year survival rates of
>75%.9,10 Although more inclusive criteria have been developed
and validated,11,12 the Milan Criteria are still considered to repre-
sent the benchmark for patient selection.8
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Chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
infections account for the majority of cases of HCC worldwide.
Although both are widely accepted as risk factors for HCC,13,14 their
carcinogenic mechanisms differ at both the molecular and mor-
phologic levels,14,15 and the prognostic interdependence of viral
status (the presence or absence of HBV or HCV) and HCC has been
controversial. Patients infected with both viruses may develop
HCC through additive (or possibly synergistic) cellular mecha-
nisms,14,16,17 and may have a worse prognosis than seronegative
HCC patients.13 By contrast, several reports have found that HBV
superinfection in previously HCV+ patients suppresses HCV rep-
lication.18,19 Likewise, other series have found that HCV superin-
fection can inhibit HBV replication.18,20 Extending this concept to
transplantation, several reports suggest that graft survival (GS) and
overall survival (OS) in HBV+/HCV+ recipients are greater than in
HBV-/HCV+ recipients.21–23 These reports, however, encompass
liver transplantation for all indications and are not specific to
patients with HCC.
In theory, cancer progression poses the greater threat to life,
making viral status a negligible contributing variable in patient
survival following liver transplantation for HCC. One study con-
cluded that HCV+ patients transplanted for HCC have a poorer
prognosis than seronegative HCC patients undergoing trans-
plant.1 By contrast, another report showed a higher post-
transplant 4-year OS in HCV+ HCC patients (72%) than in
seronegative HCC patients (68%).3 To the present authors’ knowl-
edge, no prior reports have studied the effects of HBV infection on
survival in patients undergoing liver transplantation for HCC.
The objective of this study was to stratify for risk patients under-
going transplantation for HCC according to their HBV and HCV
viral status. The study sought to verify the hypothesis that viral
status is an independent predictor of retransplantation rates, GS
and OS in patients undergoing liver transplantation for HCC.
Materials and methods
The United Network for Organ Sharing (UNOS) Standard Trans-
plant Analysis and Research Files were used to obtain records for
all patients undergoing liver transplantation from September 1987
until January 2012. This study was exempt from institutional
review board oversight. Liver diagnosis codes 4400 and 4401 were
used to identify patients transplanted for HCC and to determine
the presence of cirrhosis. Status for HBV infection was elucidated
by recipient surface antigen testing; HCV status was established by
recipient viral serology. Because viral status represented the
primary variable of interest, all patients whose HBV or HCV viral
status was coded as ‘not done’ or ‘unknown’ were excluded.
Patients were stratified into four groups by viral status: HBV-/
HCV-; HBV+/HCV-; HBV-/HCV+, and HBV+/HCV+. To study
trends in the prevalences of HBV and HCV infection among
transplanted patients, patients were divided into three groups
based on their date of transplant for the periods 1987–1999, 2000–
2004 and 2005–2012. Each group was duration-weighted to
account for the increasing number of transplants performed in
recent years. These groups were also used to analyse trends over
the last several decades in viral status, retransplantation rates, GS
and OS in transplanted HCC patients.
The primary endpoints were rates of retransplantation, GS and
OS stratified by viral status. Graft survival was defined as the time
(in months) from initial transplant to either the date of retrans-
plantation or end of follow-up. Overall survival was defined as the
time (in months) from initial transplant until either death or end
of follow-up. To ensure that the present results would be repre-
sentative of modern selection criteria, only the cohort trans-
planted during the period 2005–2012 was included for these
primary endpoints. Several other known potential prognostic
variables were included in this study to avoid the limitations of
empirically derived models, including age, Model for End-stage
Liver Disease (MELD) score, body mass index (BMI), gender, race,
cirrhosis, pre-transplant diabetes status, and antiviral treatments.
Donor viral status was also accounted for.
Statistical significance was set at a = 0.05; all tests were two-
sided. Similarity between group characteristics was determined
using the Kruskal–Wallis test (for continuous variables) and Fish-
er’s exact test (for categorical variables). Survival curves were
compared with the log-rank test for equality of survivor func-
tions. Factors predictive of the need for retransplantation were
identified with logistic regression. Variables associated with GS
and OS were identified using Cox proportional hazards models.
Univariate and multivariate models were generated for each
regression analysis. Final adjusted models automatically included
viral status (the primary variable of interest) and were otherwise
limited to significant variables by backwards selection. stata
Version 12 IC (StataCorp LP, College Station, TX, USA) was used
for all statistical tests.
Results
Of 10 353 patients who underwent liver transplantation for HCC
between September 1987 and January 2012, 8880 had known HBV
and HCV status; patient characteristics are shown in Table 1. The
majority of patients transplanted for HCC were HCV+ (n = 5721,
64%) and relatively few were HBV+ (n = 798, 9%).
Changes in viral status over time
An examination of the entire dataset (1987–2012) revealed an
increase in the proportion of HBV-/HCV+ patients who under-
went transplantation for HCC until 2000 (from 51% to 62%),
whereas the distribution of viral status among the study cohort
remained steady over the subsequent 12 years (Fig. 1a). Patients
who were HBV+/HCV- demonstrated general trends toward
fewer retransplantations (Fig. 1b) and the highest rates of 5-year
GS and OS (Fig. 1c, d). Although a cursory examination of
retransplantation rates over time might suggest that modern rates
are lower (Fig. 1b), this certainly represents lead-time bias and
should not be considered as a measure of improved quality.
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Impact of viral status on primary endpoints
To ensure that the present results would reflect modern selection
criteria, this analysis of the primary endpoints was limited to the
7060 patients transplanted between 2005 and 2012. Cold and
warm ischaemia times were similar between groups (P = 0.545 and
P = 0.556, respectively) (Table 2). In comparison with patients in
the other viral status groups, HBV+/HCV- patients had lower
MELD scores and were predominantly of Asian descent. Retrans-
plantation was performed in 71 HBV-/HCV- patients (4%), 11
HBV+/HCV- patients (2%), 173 HBV-/HCV+ patients (4%),
and three HBV+/HCV+ patients (2%) (P = 0.250). On univariate
analysis, retransplantation rates were found to correlate only with
patient age and gender (Table 3): younger and male patients were
more likely to undergo retransplantation.
Five-year GS was highest in HBV+/HCV- patients (75%) com-
pared with HBV-/HCV- (63%), HBV-/HCV+ (60%) and HBV+/
HCV+ (60%) patients (P < 0.0001) (Fig. 2). Similarly, 5-year OS
Table 1 Characteristics of 8880 patients transplanted for hepatocel-
lular carcinoma (1987–2012)
Age, years, median (IQR) 57 (53–62)
MELD score, median (IQR) 13 (9–18)
BMI, median (IQR) 27.8 (24.8–31.5)
Gender, n (%)
Female 1931 (22%)
Male 6949 (78%)
Race, n (%)
White 5777 (65%)
African-American 765 (9%)
Asian 779 (9%)
Hispanic 1436 (16%)
Other 123 (1%)
Cirrhosis, n (%)
No 2347 (26%)
Yes 6533 (74%)
Diabetes, n (%)
No 6339 (71%)
Yes 2422 (27%)
Unknown 119 (0.01%)
Viral status, n (%)
HBV-/HCV- 2530 (28%)
HBV+/HCV- 629 (7%)
HBV-/HCV+ 5552 (62%)
HBV+/HCV+ 169 (2%)
Era, n (%)
Pre-2000 482 (5%)
2000–2004 1338 (15%)
2005–2012 7060 (80%)
IQR, interquartile range; MELD, Model for End-stage Liver Disease; BMI,
body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus.
Figure 1 (a) Distribution of viral status in patients undergoing liver
transplantation for hepatocellular carcinoma (HCC), and its effect on
(b) retransplantation rates, (c) graft survival and (d) overall survival
over the 25 years from September 1987 to January 2012
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Table 2 Characteristics of 7060 patients transplanted for hepatocellular carcinoma by viral status (2005–2012)
HBV-/HCV- HBV+/HCV- HBV-/HCV+ HBV+/HCV+ P-value
(n = 1967) (n = 485) (n = 4470) (n = 138)
Age, years, median (IQR) 61 (56–65) 56 (50–62) 57 (53–60) 57 (52–60) 0.0001
MELD score, median (IQR) 14 (10–19) 9 (7–14) 13 (9–18) 12 (8–18) 0.0001
BMI, median (IQR) 29.0 (25.5–33.1) 25.2 (22.9–28.1) 28.1 (25.1–31.4) 26.5 (23.8–30.8) 0.0001
Gender, n (%) <0.001
Female 514 (26%) 82 (17%) 917 (21%) 23 (17%)
Male 1453 (74%) 403 (83%) 3553 (79%) 115 (83%)
Race, n (%) <0.001
White 1392 (71%) 127 (26%) 2977 (67%) 83 (60%)
African-American 78 (4%) 48 (10%) 478 (11%) 18 (13%)
Asian 112 (6%) 283 (58%) 193 (4%) 21 (15%)
Hispanic 353 (18%) 21 (4%) 758 (17%) 15 (11%)
Other 32 (2%) 6 (1%) 64 (1%) 1 (1%)
Cirrhosis, n (%) <0.001
No 621 (32%) 147 (30%) 976 (22%) 41 (30%)
Yes 1346 (68%) 338 (70%) 3494 (78%) 97 (70%)
Diabetes, n (%) <0.001
No 1154 (59%) 388 (80%) 3374 (75%) 104 (75%)
Yes 797 (41%) 94 (19%) 1053 (24%) 33 (24%)
Unknown 16 (1%) 3 (1%) 43 (1%) 1 (1%)
Cold ischaemia time, h, median 6.8 6.5 6.8 6.1 0.545
Warm ischaemia time, min, median 10 14 10 12 0.556
HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, interquartile range; MELD, Model for End-stage Liver Disease; BMI, body mass index.
Figure 2 Graft survival in patients transplanted for hepatocellular carcinoma (HCC) during 2005–2012, by viral status
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was highest in HBV+/HCV- patients (78%) compared with
HBV-/HCV- (66%), HBV-/HCV+ (64%) and HBV+/HCV+
(62%) patients (P = 0.0003) (Fig. 3). In unadjusted models, GS
(Table 4) and OS (Table 5) were both associated with age, MELD
score, race, diabetes status and viral status. Few patients had been
treated with either lamivudine (n = 162) or hepatitis B immu-
noglobulin (n = 383). Although lamivudine therapy was not asso-
ciated with either GS or OS, univariate analysis showed that
hepatitis B immunoglobulin was associated with prolonged OS in
HBV-infected patients.
Multivariable (adjusted) analysis
Table 6 summarizes independent predictors of need for retrans-
plantation and prognostic factors for GS and OS. Older patients
were less likely to undergo retransplantation, and had poorer GS
and OS. Patients with diabetes and those with higher MELD
scores had poorer GS and OS, and African-Americans experienced
poorer OS compared with patients of other races.
After controlling for other factors, viral status was a significant
independent predictor of outcome for all primary endpoints
(Table 6). HBV-/HCV+ patients were retransplanted more often
than HBV+/HCV- patients (P = 0.005). Graft longevity was
lowest in HBV-/HCV+ patients and greatest in HBV+/HCV-
patients. Both HBV-/HCV- and HBV+/HCV- patients lived
longer after transplantation than HBV-/HCV+ patients. None of
the antiviral therapies had a significant impact on outcome in
final adjusted analyses.
Discussion
Using data based on modern selection criteria in HCC, this study
finds that pre-transplant HBV and HCV status carries significant
independent prognostic value. Mono-infected HCV+ patients
Table 3 Univariate logistic regression analysis of factors associated
with retransplantation in patients with hepatocellular carcinoma
(HCC)
Odds ratio (95% CI) P-value
Age 0.98 (0.97–0.99) 0.003
MELD score 0.99 (0.98–1.01) 0.221
BMI 1.01 (1.00–1.03) 0.085
Gender 0.041
Female 1.00
Male 1.39 (1.01–1.89)
Race 0.372
White 1.00
African-American 1.08 (0.72–1.64) 0.701
Asian 0.78 (0.48–1.26) 0.314
Hispanic 1.23 (0.91–1.68) 0.182
Other 1.57 (0.68–3.63) 0.289
Cirrhosis 0.500
No 1.00
Yes 0.91 (0.70–1.19)
Diabetes 0.863
No 1.00
Yes 0.98 (0.75–1.27)
Viral status 0.200
HBV-/HCV- 1.00
HBV+/HCV- 0.62 (0.33–1.18) 0.145
HBV-/HCV+ 1.08 (0.81–1.42) 0.614
HBV+/HCV+ 0.59 (0.18–1.91) 0.381
95%CI, 95%confidence interval;MELD,Model for End-stage Liver Disease;
BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus.
Table 4 Univariate Cox regression analysis of factors associated
with graft survival in patients transplanted for hepatocellular
carcinoma
Hazard ratio (95% CI) P-value
Age 1.01 (1.01–1.02) <0.001
MELD score 1.01 (1.01–1.02) <0.001
BMI 1.01 (1.00–1.02) 0.138
Gender 0.406
Female 1.00
Male 1.05 (0.93–1.19)
Race 0.002
White 1.00
African-American 1.19 (1.01–1.40) 0.036
Asian 0.73 (0.60–0.89) 0.002
Hispanic 0.97 (0.85–1.12) 0.688
Other 0.49 (0.50–1.24) 0.305
Cirrhosis 0.742
No 1.00
Yes 0.98 (0.88–1.10)
Diabetes 0.017
No 1.00
Yes 1.14 (1.02–1.27)
Lamivudine therapy 0.089
No 1.00
Yes 0.30 (0.07–1.20)
Hepatitis B immunoglobulin 0.219
No 1.00
Yes 0.67 (0.36–1.27)
Viral status <0.001
HBV-/HCV- 1.00
HBV+/HCV- 0.67 (0.52–0.85) 0.001
HBV-/HCV+ 1.13 (1.01–1.27) 0.030
HBV+/HCV+ 0.97 (0.67–1.42) 0.894
95% CI, 95% confidence interval; MELD, Model for End-stage Liver
Disease; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C
virus.
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achieve poorer GS and OS compared with both seronegative
patients and mono-infected HBV+ patients.
Previous reports have attempted to recognize viral status as a
useful prognostic tool in transplanted HCC patients, but results
have been inconsistent.1,3 In a 2002 single-institution study, Moya
et al.1 found that 5-year OS in transplanted HCC patients was
worse in patients who were infected with HCV (59% versus 77%).
Although it was anticipated that viral status would help to define
the role of liver transplantation in HCC, there is no discussion of
HBV or HCV infection in several recent reviews and consensus
statements8–10 on the topic. Several series describing liver resection
for HCC have also attempted to highlight the prognostic value of
viral status. Whereas some series found that patients infected with
HCV have increased rates of recurrence24 and poorer survival,25
Table 5 Univariate Cox regression analysis of factors associated
with overall survival
Hazard ratio (95% CI) P-value
Age 1.02 (1.01–1.03) <0.001
MELD score 1.02 (1.01–1.02) <0.001
BMI 1.00 (0.99–1.01) 0.478
Gender 0.909
Female 1.00
Male 1.01 (0.88–1.15)
Race <0.001
White 1.00
African-American 1.24 (1.04–1.48) 0.018
Asian 0.72 (0.58–0.89) 0.003
Hispanic 0.93 (0.80–1.09) 0.368
Other 0.64 (0.37–1.10) 0.105
Cirrhosis 0.844
No 1.00
Yes 0.99 (0.87–1.12)
Diabetes 0.010
No 1.00
Yes 1.17 (1.04–1.31)
Lamivudine therapy 0.803
No 1.00
Yes 0.95 (0.66–1.37)
Hepatitis B immunoglobulin 0.008
No 1.00
Yes 0.69 (0.53–0.91)
Viral status <0.001
HBV-/HCV- 1.00
HBV+/HCV- 0.68 (0.52–0.88) 0.004
HBV-/HCV+ 1.14 (1.01–1.29) 0.034
HBV+/HCV+ 1.05 (0.71–1.57) 0.799
95% CI, 95% confidence interval; MELD, Model for End-stage Liver
Disease; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C
virus.
Table 6 Multivariable analyses of prognostic factors for retransplan-
tation, graft survival, and overall survival following liver transplanta-
tion for hepatocellular carcinoma
Factors associated with retransplantation
Odds ratio (95% CI) P-value
Age 0.98 (0.96–0.99) 0.003
Viral status <0.001
HBV-/HCV- 1.00
HBV+/HCV-a 0.57 (0.30–1.08) 0.087
HBV-/HCV+a 1.03 (0.77–1.36) 0.859
HBV+/HCV+ 0.57 (0.18–1.83) 0.342
Factors associated with graft survival
Hazard ratio (95% CI) P-value
Age 1.02 (1.01–1.02) <0.001
MELD score 1.02 (1.01–1.02) <0.001
Diabetes 0.019
No 1.00
Yes 1.14 (1.02–1.27)
Viral status <0.001
HBV-/HCV- 1.00
HBV+/HCV-b 0.76 (0.59–0.98) 0.033
HBV-/HCV+b 1.25 (1.11–1.41) <0.001
HBV+/HCV+ 1.03 (0.70–1.51) 0.883
Factors associated with overall survival
Hazard ratio (95% CI) P-value
Age 1.02 (1.02–1.03) <0.001
MELD score 1.02 (1.01–1.03) <0.001
Race 0.022
White 1.00
African-American 1.22 (1.02–1.46) 0.028
Asian 0.89 (0.70–1.13) 0.343
Hispanic 0.90 (0.77–1.05) 0.171
Other 0.65 (0.37–1.12) 0.120
Diabetes 0.012
No 1.00
Yes 1.16 (1.03–1.31)
Viral status <0.001
HBV-/HCV- 1.00
HBV+/HCV-c 0.85 (0.63–1.13) 0.263
HBV-/HCV+c 1.29 (1.13–1.47) <0.001
HBV+/HCV+ 1.18 (0.79–1.76) 0.424
95% CI, 95% confidence interval; HBV, hepatitis B virus; HCV, hepatitis
C virus; MELD, Model for End-stage Liver Disease.
aSignificantly different odds ratios (P = 0.005) when directly compared.
bSignificantly different hazard ratios (P < 0.001) when directly compared.
cSignificantly different hazard ratios (P = 0.003) when directly compared.
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others found that viral status did not impact outcomes.26 Pawlik
et al.2 investigated the impacts of both HBV and HCV in resected
HCC patients and found that infection with either virus was asso-
ciated with bilobar disease. Patients mono-infected with HCV had
a higher degree of liver fibrosis and less vascular invasion. Neither
virus, however, had an impact on OS. In a recent meta-analysis of
patients undergoing resection for HCC,27 both HBV and HCV
infection were associated with poorer disease-free and overall
survival.
Co-infection with both HBV and HCV (HBV+/HCV+) has a
perplexing link with risk for and prognosis in HCC. Epidemio-
logically, several series have noted an additive or synergistic risk
for HCC in co-infected patients.14,16,17 Patients with HCV who
show serologic evidence of prior HBV infection tend to have
higher rates of non-cirrhotic HCC, poorly differentiated HCC,
and poorer survival rates after resection.14,28 The X gene of HBV
has been implicated in the synergistic risk for HCC in co-infected
patients; however, these mechanisms are not firmly established.14
Given these associations between co-infection and risk for HCC, it
is somewhat surprising that several series have described
improved outcomes in HBV+/HCV+ patients after liver trans-
plantation. In small studies, co-infected patients have exhibited
GS21 and OS22,23 superior to those in their HBV-/HCV+ counter-
parts. Although some viruses are known to inhibit the replication
of other secondary viruses at a molecular level, HBV and HCV
have not been shown to interfere with the replication of one
another in vitro.18 If viral interference truly exists in HBV+/HCV+
patients after transplantation, it most likely occurs through host
adaptive or innate immune properties. In the present study, the
co-infected population was relatively small (n = 138). Although
HBV+/HCV+ patients showed trends toward fewer retransplan-
tations, prolonged GS and prolonged OS compared with HBV-/
HCV+ patients, these differences were not statistically significant.
Few patients were treated with antiviral therapy and, despite its
theoretical benefit, improved outcomes were not demonstrated.
In addition to viral status, several other variables (age, MELD
score, presence of diabetes and race) were found to influence the
primary endpoints in the present study. The presence of diabetes
has been shown to increase risk for HCC in patients with concur-
rent HBV or HCV infection or alcoholic cirrhosis,29 but has not
previously been associated with outcome following liver trans-
plantation for HCC. This oncogenic association may be linked to
obesity and metabolic syndrome, and the risk for HCC associated
with non-alcoholic steatohepatitis.14 Indeed, one study linked
higher BMI to early death in seronegative patients who underwent
transplant,30 but another study found higher BMI to have no
influence on short- or longterm outcomes.31 In the present study,
BMI did not show prognostic significance in adjusted models.
Race has also been associated with outcome after liver transplan-
tation for HCC. African-American patients have higher rates of
chronic graft failure, poorer GS and poorer OS.32–34 Although the
present study did not find race to be independently predictive of
retransplantation rates or GS, it did establish a poorer OS in
African-Americans. Increased age also predicted poorer GS and
OS in this study, a finding that aligns with those cited in previous
reports.32
Initially, the present study was designed to also examine the
influence of donor HBV and HCV status on outcomes; however,
no donors in this study sample were coded as HBV+ or HCV+.
Registry datasets such as that of UNOS are known to suffer from
miscoding; nonetheless, no conclusions can be drawn about the
impact of donor viral status on the primary endpoints of the
Figure 3 Overall survival in patients transplanted for hepatocellular carcinoma (HCC) during 2005–2012, by viral status
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current study. This registry also lacks potentially informative data
on viral loads; accordingly, response to antiviral medications
cannot be assessed. Although the study population was intention-
ally limited, complete records of viral status were available for
7060 (91%) of the 7742 patients who were transplanted for HCC
from 2005. The generalizability of these results assumes that all
transplanted patients met modern selection criteria, but this
dataset does not allow for specific adjustment for several onco-
logic staging parameters, such as tumour size, multifocality and
vascular invasion. Because the timing of recurrence was not
recorded, recurrence-free and disease-free survival analyses are
not possible.
In conclusion, HBV and HCV viral status influences prognosis
in patients undergoing liver transplantation for HCC. After
adjusting for other covariates, HBV-/HCV+ patients achieve
poorer GS and OS compared with both HBV-/HCV- and HBV+/
HCV- patients. Both patients and physicians should understand
the ramifications of viral status on post-transplant outcomes in
HCC patients, especially in an era in which the allocation of grafts
is carefully scrutinized.
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